Back to Feed
ClinicalTrials.gov|Clinical Trial
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Abstract
This is a First-in-Human, open-label, early dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC trial participants. Phase: PHASE1 Status: RECRUITING Conditions: Relapsed/Refractory Small Cell Lung Cancer Interventions: GC511B CAR-T Cell Injection
Keywords
Relapsed/Refractory Small Cell Lung Cancer